Zoetis Inc.

ZTS Healthcare Drug Manufacturers Specialty & Generic

Zoetis Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.5 billion, up 2.28% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 2.48%, free cash flow grew 17.4% and total debt rose 37.5%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years, revenue growth for ten; insiders bought in the last twelve months.

79.20 0.78 +0.99%
Market cap
$32.4B
P/E
13.0×
Fwd P/E
12.3×
Dividend yield
3.31%
F-score
7/9
Altman Z
5.73
Beneish M
−2.45
Dividend safety
88/100
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
P/E ratio
20.87 29.73 38.77 32.56 56.75 48.11 42.15 29.00 40.78 32.48
Piotroski F-Score
7 8 9 4 9 7 6 6 8 7
P/S ratio
5.89 8.00 10.61 8.52 14.89 11.79 10.11 7.09 6.63 5.43
Altman Z-Score
5.73 7.51 8.59 6.26 9.79 6.80 6.26 4.79 5.17 4.46
Altman Z″-Score (non-manufacturers)
6.66 6.04 6.45 5.54 5.93 5.00 4.42 4.37 4.79 4.06
P/FCF ratio
24.44 32.20 55.92 51.89 66.60 46.46 46.67 27.40 30.34 45.26
Beneish M-Score
(2.45) (2.61) (2.36) (2.38) (2.44) (2.76) (2.58) (2.51) (2.67) (2.39)
P/Operating CF
62.48 81.77 101.06 92.92 170.48 109.60 108.73 70.76 57.83 92.89
Dividend Safety Score
88 — — — — — — — — —
P/B ratio
16.34 15.51 18.16 15.64 25.47 20.86 23.37 18.91 19.69 17.72
Price to Tangible BV
0.00 80.53 101.40 248.58 298.34 0.00 0.00 0.00 0.00 0.00
EV/Sales
6.73 8.49 11.14 9.06 15.29 12.33 10.83 7.91 7.41 6.20
EV/EBITDA
15.66 20.39 25.96 21.90 37.63 30.84 27.83 20.90 20.24 18.55
EV/Operating CF
21.95 26.61 40.45 38.27 53.73 38.71 37.77 25.74 29.20 42.51
EV/FCF
27.92 34.20 58.72 55.15 68.41 48.58 50.00 30.55 33.91 51.64
Quick Ratio
1.75 0.97 1.77 1.51 2.57 2.13 1.67 2.24 2.34 1.47
Current Ratio
3.03 1.75 3.36 2.37 3.86 3.05 2.63 3.60 3.85 3.03
Net Debt/EBITDA
1.65 1.19 1.23 1.29 1.00 1.35 1.85 2.16 1.75 2.29
Debt/Assets
58.46% 46.15% 45.97% 52.96% 47.72% 52.90% 55.84% 59.87% 57.69% 58.41%
Debt/Equity
2.71 1.38 1.32 1.80 1.46 1.91 2.38 2.95 2.77 2.98
Asset Turnover
0.64 0.65 0.59 0.56 0.57 0.53 0.56 0.60 0.65 0.63
Operating CF/Net income
1.09 1.19 1.00 0.90 1.09 1.30 1.20 1.25 1.56 0.87
Capex/Depreciation
(1.28) (1.32) (1.49) (1.26) (1.06) (0.98) (1.07) (0.92) (0.77) (0.52)
Interest Coverage
16.14 14.92 13.28 13.02 12.11 9.64 9.08 9.20 9.71 8.40
ROE
65.99% 50.94% 49.90% 47.26% 48.98% 50.55% 61.31% 71.92% 52.60% 63.40%
ROA
18.00% 17.43% 16.05% 14.67% 14.81% 13.02% 13.44% 14.75% 10.64% 10.55%
ROIC
20.87% 20.94% 19.28% 19.02% 20.22% 16.93% 15.59% 15.23% 18.42% 14.65%
Return on Tangible Assets
32.54% 41.68% 30.61% 29.81% 26.96% 24.66% 30.73% 29.54% 18.96% 22.47%
Average Days of Receivables
61.30 51.90 55.71 54.89 53.18 55.39 63.32 64.92 68.64 68.18
Research and Development Expense of Revenue
7.37% 7.41% 7.19% 6.67% 6.53% 6.94% 7.30% 7.42% 7.20% 7.69%
Selling, General and Administrative Expense of Revenue
25.12% 25.04% 25.18% 24.86% 25.73% 25.86% 26.17% 25.48% 25.14% 27.91%
Intangible Assets out of Total Assets
0.24 0.27 0.29 0.28 0.30 0.32 0.39 0.42 0.32 0.35
Share Based Compensation of Revenue
0.88% 0.80% 0.70% 0.77% 0.75% 0.88% 1.07% 0.91% 0.83% 0.76%
Graham Net Nets
(0.09) (0.05) (0.03) (0.04) (0.02) (0.04) (0.06) (0.10) (0.07) (0.10)
Graham Number
32.32 35.98 35.14 30.87 30.44 24.78 20.00 17.33 12.02 10.60
Earnings Yield
4.79% 3.36% 2.58% 3.07% 1.76% 2.08% 2.37% 3.45% 2.45% 3.08%
Free Cash Flow Yield
4.09% 3.11% 1.79% 1.93% 1.50% 2.15% 2.14% 3.65% 3.30% 2.21%
Revenue per Share
21.35 20.38 18.53 17.23 16.39 14.04 13.09 12.06 10.83 9.86
Operating CF per Share
6.55 6.50 5.10 4.08 4.67 4.47 3.75 3.71 2.75 1.44
Capex per Share
(1.40) (1.44) (1.59) (1.25) (1.00) (0.91) (0.92) (0.58) (0.38) (0.25)
Free Cash Flow per Share
5.15 5.06 3.52 2.83 3.66 3.56 2.84 3.12 2.37 1.18
Cash per Share
5.21 4.37 4.43 7.64 7.35 7.58 4.04 3.52 3.19 1.47
Shareholders Equity per Share
7.51 10.50 10.82 9.39 9.58 7.93 5.66 4.52 3.65 3.02
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
7.51 10.50 10.82 9.39 9.58 7.93 5.66 4.52 3.65 3.02
Free Cash Flow
2,283.00 2,298.00 1,621.00 1,327.00 1,738.00 1,694.00 1,356.00 1,508.00 1,159.00 587.00
Working Capital
4,533.00 2,574.00 4,454.00 4,339.00 5,133.00 4,441.00 2,942.00 3,176.00 3,123.00 2,273.00
Capital Expenditures
(621.00) (655.00) (732.00) (585.00) (475.00) (432.00) (439.00) (282.00) (187.00) (126.00)
Net Current Asset Value
(5,368.00) (3,481.00) (2,952.00) (3,016.00) (2,426.00) (3,225.00) (4,089.00) (4,193.00) (2,583.00) (2,760.00)
EV/EBIT
17.79 23.40 29.98 25.44 43.84 36.95 33.49 24.30 23.12 21.74
Capex to Sales
0.07 0.07 0.09 0.07 0.06 0.06 0.07 0.05 0.04 0.03
Price to Operating Income
16.61 23.62 30.88 25.92 46.53 39.43 35.14 24.45 23.06 21.63
Other line items
Depreciation/Fixed assets
0.13 0.15 0.15 0.17 0.19 0.20 0.21 0.19 0.17 0.17
Cash ROIC
15.55% 17.24% 11.92% 8.35% 11.85% 11.62% 12.23% 14.59% 13.96% 8.77%
Accounts Receivable Turnover
6.52 7.07 6.78 6.88 7.25 6.36 5.90 5.73 5.55 5.28
Accounts Payable Turnover
5.80 6.44 6.28 5.84 5.16 5.43 6.49 6.66 6.75 5.97
Inventory Turnover
1.13 1.12 1.04 1.15 1.30 1.35 1.42 1.36 1.21 1.12
Average Days of Payables
66.67 58.13 58.58 60.24 69.10 81.09 55.15 59.78 53.67 58.06
Days of Inventory on Hand
332.69 309.56 365.43 348.79 304.77 288.88 258.36 265.68 293.44 329.07
Average Receivables
1,453.00 1,310.00 1,259.50 1,174.00 1,073.00 1,049.50 1,061.00 1,017.00 955.50 925.00
Average Payables
460.00 422.00 408.00 420.50 446.50 379.00 307.00 287.00 263.00 279.00
Average Inventory
2,368.00 2,435.00 2,454.50 2,134.00 1,775.50 1,519.00 1,400.50 1,409.00 1,464.50 1,484.50
Average Assets
14,852.00 14,261.50 14,605.50 14,412.50 13,754.50 12,577.00 11,161.00 9,681.50 8,117.50 7,781.00
Average Common Equity
4,050.50 4,880.50 4,697.00 4,473.50 4,158.50 3,240.50 2,446.50 1,985.50 1,642.50 1,295.00

Fold the line items

Columns are period end dates